BioNTech Future Growth
Future criteria checks 0/6
BioNTech's revenue and earnings are forecast to decline at 29.4% and 38.6% per annum respectively while EPS is expected to decline by 41.1% per annum.
Key information
-38.6%
Earnings growth rate
-41.1%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | -29.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 5,681 | 1,924 | 1,517 | 1,838 | 5 |
12/31/2024 | 5,869 | 2,320 | 2,624 | 4,257 | 12 |
12/31/2023 | 9,440 | 4,509 | 6,415 | 8,173 | 14 |
12/31/2022 | 16,476 | 8,714 | 20,483 | 17,149 | 13 |
9/30/2022 | 18,565 | 10,322 | 12,277 | 12,549 | N/A |
6/30/2022 | 21,191 | 11,748 | 9,040 | 9,271 | N/A |
3/31/2022 | 23,303 | 12,863 | 5,066 | 5,251 | N/A |
12/31/2021 | 18,977 | 10,293 | 736 | 890 | N/A |
9/30/2021 | 13,790 | 7,493 | 1,198 | 1,338 | N/A |
6/30/2021 | 7,770 | 4,072 | -474 | -355 | N/A |
3/31/2021 | 2,503 | 1,197 | -376 | -270 | N/A |
12/31/2020 | 482 | 15 | -99 | -13 | N/A |
9/30/2020 | 165 | -410 | -382 | -326 | N/A |
6/30/2020 | 126 | -230 | -239 | -183 | N/A |
3/31/2020 | 110 | -192 | -268 | -222 | N/A |
12/31/2019 | 109 | -179 | -270 | -198 | N/A |
9/30/2019 | 144 | -122 | -220 | -138 | N/A |
6/30/2019 | 136 | -116 | -142 | -75 | N/A |
3/31/2019 | 132 | -77 | -136 | -55 | N/A |
12/31/2018 | 128 | -48 | -126 | -59 | N/A |
12/31/2017 | 62 | -86 | -110 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 22UA's earnings are forecast to decline over the next 3 years (-38.6% per year).
Earnings vs Market: 22UA's earnings are forecast to decline over the next 3 years (-38.6% per year).
High Growth Earnings: 22UA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 22UA's revenue is expected to decline over the next 3 years (-29.4% per year).
High Growth Revenue: 22UA's revenue is forecast to decline over the next 3 years (-29.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 22UA's Return on Equity is forecast to be high in 3 years time